Provided by Tiger Fintech (Singapore) Pte. Ltd.

Fulcrum Therapeutics

6.92
-0.0100-0.14%
Post-market: 6.920.00000.00%13:42 EDT
Volume:146.36K
Turnover:999.54K
Market Cap:373.54M
PE:-842.77
High:6.95
Open:6.95
Low:6.65
Close:6.93
Loading ...

Fulcrum Therapeutics price target raised to $6 from $2 at BofA

TIPRANKS
·
01 Jul

Fulcrum Therapeutics Elects New Directors at Annual Meeting

TIPRANKS
·
28 Jun

Fulcrum Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
28 Jun

BRIEF-Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule

Reuters
·
07 Jun

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
07 Jun

Fulcrum Therapeutics Inc. to Present at 5th Global Congress on Sickle Cell Disease and European Hematology Association Congress

Reuters
·
30 May

Fulcrum Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
30 May

Fulcrum Therapeutics price target raised to $9 from $6 at Piper Sandler

TIPRANKS
·
29 May

Sector Update: Health Care Stocks Decline Late Afternoon

MT Newswires Live
·
24 May

Fulcrum Therapeutics Shares Rise After Upgrade From Leerink

MT Newswires Live
·
24 May

Fulcrum Therapeutics Shares up 10% After Leerink Partners Raises to Outperform From Market Perform

THOMSON REUTERS
·
23 May

Fulcrum Therapeutics Raised to Outperform From Market Perform by Leerink Partners

Dow Jones
·
23 May

Leerink Upgrades Fulcrum Therapeutics to Outperform From Market Perform, Adjusts Price Target to $12 From $4

MT Newswires Live
·
23 May

Fulcrum Therapeutics Shares up 3.7% Premarket After Leerink Partners Raises to Outperform From Market Perform

THOMSON REUTERS
·
23 May

Fulcrum Therapeutics upgraded to Outperform from Market Perform at Leerink

TIPRANKS
·
23 May

Fulcrum Therapeutics (FULC) Receives a Buy from Oppenheimer

TIPRANKS
·
16 May

Fulcrum Therapeutics Shares Rise After Cantor Fitzgerald Upgrade

MT Newswires Live
·
16 May

Fulcrum Therapeutics Raised to Overweight From Neutral by Cantor Fitzgerald

Dow Jones
·
15 May

Cantor Fitzgerald Upgrades Fulcrum Therapeutics to Overweight From Neutral, Price Target is $10

MT Newswires Live
·
15 May

CAMP4 Therapeutics Reports Q1 2025 Financial Results: Net Loss Slightly Decreases to $12.4 Million

Reuters
·
14 May